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Cerebral autosomal dominant arteriopathy with subcortical
infarcts and leukoencephalopathy (CADASIL) is a relatively
rare hereditary small vessel disease resulting in neurological
deficits [1]. Stroke and transient ischaemic attack (TIA) are
reported in the majority with symptomatic CADASIL, driving
presentation in 71% in a large case series, migraine is common
(23%) and life expectancy is reduced [1, 2]. CADASIL can
also contribute to vascular dementia. The exact prevalence of
CADASIL is unknown as it is under-recognised even in spe-
cialist stroke settings, but the minimum prevalence is estimat-
ed at 2–5 in 100,000 [1].
Previous CADASIL studies have generally involved
genotyping for patients presenting with repeated strokes, with
several missense (amino-acid substituting) mutations in the
NOTCH3 gene reported [3]. Many, often rare, mutations have
been linked to CADASIL. However, population-based esti-
mates of the predictive value of NOTCH3missense mutations
in community samples are unknown. With increasing avail-
ability of genotyping, including in clinical biobanks and direct
to consumers, data are needed on the true penetrance of
NOTCH3 mutations.
We aimed to estimate cerebrovascular outcomes associated
with all missense (amino-acid altering) likely pathogenic vari-
ants inNOTCH3 in 451,424 participants of European descent in
the UK Biobank (UKB) volunteer study. UKB community vol-
unteers consented for genotyping and baseline (2006–2010)
physiological measures, including systolic and diastolic blood
pressure (BP), plus demographics and medical history [4]. The
cohort was linked to national hospital inpatient and death cer-
tificate records and followed up for a mean of 7 years (maxi-
mum 10).We searchedUKBAffymetrix Axiom array genotype
data with imputation (v3, ~ 93million variants) for all amino-
acid substituting variants in NOTCH3 (n = 131), excluding low
imputation quality (< 80%) and in linkage disequilibrium (R2 >
0.3), leaving 22 variants for follow-up. We used the Variant
Effect Predictor (http://grch37.ensembl.org/Homo_sapiens/
Tools/VEP, accessed: 17th May 2018) tools to prioritise
variants with potential pathogenic effects; this process
identified rs201680145 (p.Arg1231Cys: 0.04% mutation
prevalence in UKB) and rs35769976 (p.Ala1020Pro; 0.96%
mutation prevalence in UKB) only. Logistic regression tested
cross-sectional associations between genotype and baseline BP,
prevalent stroke or TIA, and prevalent Coronary Heart Disease
(CHD). We used Cox proportional hazards regression models
for all-cause mortality and Fine and Gray competing risk
models for incident stroke, with all-cause mortality as the com-
peting risk. Those with prior strokes were included in the anal-
ysis of incident strokes as CADASIL is linked to recurrent
strokes.Models were adjusted for age, sex and technical genetic
covariates (including genetic principal components to account
for population admixture). Analyses were conducted using
Stata v14.1. The rs201680145 variant has been reported as
pathogenic for CADASIL by two sources [5]. There were 176
UKB participants heterozygous for the missense A allele of
rs201680145 (p.Arg1231Cys/p.R1231C, prevalence 0.04% of
451,424) and no homozygous participants. Mean age was 56.
8 years (SD 7.7, median 58, IQR 13). rs201680145 heterozy-
gotes had modest increases in baseline systolic (3.12 mmHg;
95% confidence interval 0.28 to 5.96) and diastolic blood pres-
sure (BP) (2.02 mmHg, 0.39 to 3.64), compared to no muta-
tions. Figure 1 shows the percentage of subjects developing
incident stroke or TIA, by NOTCH3 variant genotype. During
the follow-up period, four of 176 A allele rs201680145 hetero-
zygotes experienced incident strokes or TIAs (2.27%), com-
pared to 0.88% (3874/442,613) with no mutation: sub-HR 3.
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21, 1.20 to 8.56; p = 0.020. Incident CHD or all-cause mortality
was not associated with rs201680145.
There were 8596 heterozygotes for rs35769976 and only
44 G allele homozygotes (0.01% of 451,424), so we grouped
homozygotes and heterozygotes. The mean age of the sample
was 56.8 years (SD 8.0, median 58, IQR 12). Participants with
at least one rs35769976 G allele had a slightly increased dia-
stolic BP (coefficient 0.24, 0.0079 to 0.47; p value = 0.043).
There were no strokes or TIAs in the G allele homozygotes
and 77 in heterozygotes. The rs35769976 variant was not
associated with incident stroke or TIA, CHD or all-cause
mortality.
In a European Ancestry community volunteer biobank, we
have shown that only two potentially pathogenic NOTCH3
missense variants were ascertained in array genotyping data
with imputation. rs201680145, previously reported as patho-
genic by two sources [5], was associatedwith elevated systolic
and diastolic BP, plus substantially increased risk of incident
stroke or TIA. However, the great majority of rs35769976
carriers did not have a stroke or TIA, suggesting that this
mutation is associated with a milder clinical course. If these
mutations were associated with high rates of serious strokes,
we would expect prevalence of the mutations to be lower at
older ages, but neither mutation was associated with age in
UK biobank. A limitation of our analysis is that the maximum
age at end follow-up was 80 years. However, as the cohort
included those between 41 and 70 years at baseline, with up to
10-year follow-up, the important time for early strokes is cap-
tured. In addition, while 10-year follow-up is longer than in
most reported CADASIL studies, data on even longer follow-
ups would be helpful. This would also allow analysis of repeat
events in individuals, as numbers with recurrent stroke or TIA
in this cohort were too small to analyse.
This study suggests that potentially pathogenic NOTCH3
missense mutations seen in large European ancestry array ge-
notyped biobanks have relatively limited CADASIL risk pro-
files. Caution is needed in responding to incidental data on
these mutations in community volunteer samples. More work
is needed to establish whether co-factors (including higher
blood pressures) modify risks of clinical outcomes.
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